Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose vs Prandial Insulin for Gestational Diabetes
NCT03380546Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acarbose in gestational diabetes mellitus (GDM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite endpoint: birth weight ≥ 90th percentile, neonatal hypoglycemia, shoulder dystocia, birth injury. Started Jul 2018; status: terminated.
02
Drugs
acarbose
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT03380546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380546.